FDA Rejects RP1 Melanoma Therapy, Citing IGNYTE Trial Flaws

The FDA issued a complete response letter on April 10, 2026, declining to approve Replimune's RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma. The decision, which landed on the therapy's Prescription Drug User Fee Act target date, cited methodological concerns with the single-arm IGNYTE trial — not the efficacy data itself. In patients whose disease had progressed on prior anti-PD-1 therapy, RP1 plus nivolumab produced a 34% objective response rate, with a median response duration of 24.8 months and median progression-free survival of 30.6 months versus 4.4 months on the prior PD-1 regimen, according to Replimune's April 10, 2026 press release. The FDA's objection is not that the drug failed. It's that the trial design could not adequately prove that RP1 was responsible for the results.

The Science Behind RP1's Mechanism in Melanoma

Melanoma has one of the more responsive profiles to immunotherapy among solid tumors, and PD-1 checkpoint inhibitors have reshaped first-line treatment over the past decade. But a large subset of patients whose disease progresses despite PD-1 blockade have few high-efficacy options. RP1 was engineered specifically to address refractory disease using a different mechanism from conventional immunotherapy.

RP1 is built from a genetically modified herpes simplex virus type 1 (HSV-1) equipped with two additional components: a fusogenic protein that causes infected tumor cells to merge with neighboring cells before dying (amplifying tumor destruction) and granulocyte-macrophage colony-stimulating factor (GM-CSF), which recruits dendritic cells and macrophages to the tumor site. This produces a two-phase effect: direct lysis of cancer cells followed by immune cell recruitment, which transforms the tumor microenvironment into an antigen-presenting site and primes a systemic immune response. When paired with nivolumab, which blocks the PD-1 checkpoint that cancer cells use to suppress T cells, the intent was to create a compound mechanism — RP1 generates the immune signal, nivolumab removes the suppressive brake.

In the IGNYTE trial, 156 patients with confirmed progression on prior PD-1 therapy received the combination. The 30.6-month median PFS, compared to 4.4 months on the prior regimen, drew close clinical scrutiny across oncology and had previously earned the therapy a breakthrough designation from the FDA. That designation did not protect the BLA from evidentiary scrutiny.

Why Did the FDA Reject RP1 Despite a 34% Response Rate?

The FDA did not dispute the 34% objective response rate. The question was whether RP1 caused it. In accelerated approval reviews, the agency requires that the observed signal be credibly attributable to the drug under review, not to background effects from the co-administered therapy or trial design artifacts. A single-arm trial without a control group cannot establish that distinction, which is the core of the FDA's concern with IGNYTE.

The agency identified three specific problems, as detailed in Applied Clinical Trials' coverage of the CRL. The single-arm design made it impossible to determine what portion of the response reflected RP1's contribution versus residual or reawakened PD-1 sensitivity — a documented phenomenon in anti-PD-1-refractory cohorts, where some patients do respond to re-challenge or combination rechallenge. Tumor assessment methodology was inconsistent across sites, creating variability in how responses were classified. And patient population heterogeneity complicated cross-patient interpretation of durability outcomes.

None of these concerns involve safety. RP1's tolerability profile across 52 weeks of treatment was described as favorable, with adverse events largely mild to moderate and self-resolving. The CRL is entirely about whether the evidence establishes what the drug does — not whether it harms patients.

What This Means for RP1 and Melanoma Treatment

Replimune had already initiated a global Phase 3 confirmatory trial, IGNYTE-3, in response to prior FDA feedback ahead of the BLA resubmission. That trial is ongoing. But CEO Sushil Patel stated in the April 10 announcement that without accelerated approval, RP1 development is "not viable," and the company will reduce its U.S. workforce and scale back manufacturing. The financial capacity to sustain IGNYTE-3 to full enrollment is now in question.

The formal path forward involves requesting a meeting with the FDA to clarify the complete response letter's requirements. A dispute resolution process is available if Replimune contests the scientific basis for the CRL. For patients with anti-PD-1-refractory advanced melanoma, the decision extends the wait for a therapy that showed durable responses in a population with limited options. The case also reinforces how evidentiary standards in accelerated approval pathways have tightened since legislative reforms in 2022 — a shift that affects how single-arm oncology trials are designed and what contribution-of-effect data they must generate.

At the population level, UV protection protocols remain the strongest clinically validated lever for reducing melanoma incidence — the regulatory delays in advanced-disease treatment make primary prevention more important, not less. Regulatory science across skin health categories continues to tighten: Health Canada's recent cosmetic labeling reforms reflect the same pattern of evidence standards rising across the skin health spectrum.